Atlas Trials

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Clinical trial NCT02604342 · COMPLETED

Trial details

NCT number
NCT02604342
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2015-11-03
Primary completion
2017-01-26
Enrollment
119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.